{
  "ticker": "PIQ",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02973081",
  "id": "02973081",
  "pages": 14,
  "price_sensitive": true,
  "date": "20250728",
  "time": "0843",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250728/pdf/06m640sp9mzq86.pdf",
  "summary": "### **Material Information Summary \u2013 Proteomics International Laboratories Ltd (ASX: PIQ)**  \n\n#### **Capital Raising**  \n- **Type:** Share Purchase Plan (SPP) + Institutional Placement  \n- **Total Raised:** $12 million (AUD) ($7.5m SPP, $4m institutional, $0.5m directors/KMP)  \n- **Use of Proceeds:** Commercialisation of diagnostic tests (PromarkerD, Eso, Endo, OxiDx), US/AU lab expansions.  \n\n#### **Operational & Financial Highlights (Appendix 4C)**  \n- **Cash Balance (30 Jun 2025):** $11.0 million (vs. $3.1m prior quarter).  \n- **Quarterly Cash Burn:** Net operating outflow of $3.2m.  \n- **R&D Tax Incentive:** ~$2 million expected in 1H FY25.  \n- **Customer Receipts:** $201k (up from $84k prior quarter).  \n\n#### **Key Commercial Milestones**  \n1. **PromarkerD (Diabetic Kidney Disease):**  \n   - **US Launch:** Initiated at ADA Scientific Sessions; CPT PLA billing code (0579U) granted (effective 1 Oct 2025).  \n   - **Next-Gen Test:** Simplified high-throughput immunoassay with 44-fold risk discrimination (AUC 0.88).  \n   - **AU Rollout:** First sales achieved; partnership with Healius Group for national blood collection.  \n\n2. **PromarkerEso (Esophageal Cancer):**  \n   - Peer-reviewed validation: 91% sensitivity, 99% specificity.  \n   - Planned launch at ISDE World Congress (Sep 2025).  \n\n3. **PromarkerEndo (Endometriosis):**  \n   - Clinical validation: 83% sensitivity, 95% specificity.  \n   - Patent granted in Japan (first jurisdiction); AU launch targeted H2 CY25.  \n\n4. **OxiDx (Muscle Stress):**  \n   - Chinese patent granted; peer-reviewed study published for equine applications.  \n\n#### **Other Material Updates**  \n- **Funding Boost:** $6m (WA Govt, Bioplatforms Australia, UWA) for lab infrastructure.  \n- **Cash Runway:** ~3.5 quarters post-quarter (excludes $2m R&D rebate).  \n\n**No material information omitted.**",
  "usage": {
    "prompt_tokens": 11470,
    "completion_tokens": 510,
    "total_tokens": 11980,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-27T22:56:29.896129"
}